Transform Alpha-II Spectrin (SPTAN1) to a Prototype Platform for Tissue Quality Assessment
Catherine Kil, Kelly Considine, Michael C. Stankewich, Bartose Smarkucki, Jie Li, and Alexander O. Vortmeyer
Department of Pathology, Yale School of Medicine, New Haven, CT, USA
INTRODUCTION
Variable degrees of molecular degradation unavoidably occur in clinical tissue specimens. No accurate tool exists for degradation assessment and specimens are therefore analyzed without quality control.
Using proteomic comparison tools and an experimental Cold Ischemic Time (CIT) tissue degradation model, we have identified 27 Tissue Degradation Indicators (TDIs) for quantitative degradation measurement.
Alpha II spectrin (SPTAN1), one of the TDIs, undergoes continuous and dynamic conversion from its intact form to its breakdown forms during tissue degradation. The quantitative ratio between SPTAN1 intact and breakdown forms strongly correlates with the impact of CIT.
In the present study, we proceed with validation of SPTAN1 as a TDI in a large cohort of specimens and explore the transformative potential of SPTAN1 to be a tissue quality assessment tool.
©2012 Yale Department of Pathology. All rights reserved.
Any redistribution or reproduction of part or all of the contents in any form is prohibited. You may not, except with express written permission of the author or the Department of Pathology, distribute or commercially exploit the content, nor may you transmit it or store it in any other website or other form of electronic retrieval system, including use for educational purposes.